CRDF (CRDF) Stock Analysis
Verdict: AVOID
Severe cash burn (-$37.97M FCF loss) leaves CRDF with under 6 months of cash runway, making equity dilution imminent despite insider buys.
Investment score: 37/100
Cardiff Oncology is a speculative microcap biotech ($105M market cap) developing Onvansertib for KRAS-mutated colorectal cancer. Despite positive insider buys and a recent HC Wainwright upgrade to $9, an unsustainable cash burn (-$37.97M annual FCF) against $17.47M in cash poses immediate dilution risk within six months.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| GNLX | -2.78 | 6.91 | 13872.50 | -3.05 | — | -4224.13 |
| COYA | -4.50 | 0.00 | 14.10 | 1951.38 | — | -2.70 |
| PMVP | -1.04 | 1.10 | 0.00 | -0.87 | — | 0.00 |
| CADL | -8.06 | 6.68 | 0.00 | -8.20 | — | 0.00 |
| ATRA | -8.00 | -3.84 | 13.73 | -6.72 | — | -2.69 |